Luteolin has proved the ability to induce apoptosis in triple-negative breast cancer cells (ER-/PR-/HER2-), as well as to suppress angiogenesis and inhibit aromatase activity, the latter being involved in the conversion of androgens to estrogens. Here, ERBB2 is linked to triple-negative breast carcinoma.